[HTML][HTML] Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola
DS Fedson - Annals of translational medicine, 2016 - ncbi.nlm.nih.gov
There is an ongoing threat of epidemic or pandemic diseases that could be caused by
influenza, Ebola or other emerging viruses. It will be difficult and costly to develop new drugs …
influenza, Ebola or other emerging viruses. It will be difficult and costly to develop new drugs …
Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus
Ebola virus (EBOV), a member of the family Filoviridae, is responsible for causing Ebola
virus disease (EVD)(formerly named Ebola hemorrhagic fever). This is a severe, often fatal …
virus disease (EVD)(formerly named Ebola hemorrhagic fever). This is a severe, often fatal …
[HTML][HTML] Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses
Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of
lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral …
lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral …
Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection
Passive administration of monoclonal antibodies (mAbs) is a promising therapeutic
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …
Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses
Several ebolaviruses cause outbreaks of severe disease. Vaccines and monoclonal
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …
A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses
There is an urgent need for monoclonal antibody (mAb) therapies that broadly protect
against Ebola virus and other filoviruses. The conserved, essential interaction between the …
against Ebola virus and other filoviruses. The conserved, essential interaction between the …
[HTML][HTML] Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability
X Zhao, KA Howell, S He, JM Brannan, AZ Wec… - Cell, 2017 - cell.com
While neutralizing antibodies are highly effective against ebolavirus infections, current
experimental ebolavirus vaccines primarily elicit species-specific antibody responses. Here …
experimental ebolavirus vaccines primarily elicit species-specific antibody responses. Here …
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection
Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome
maturation that emerged from a haploid genetic screen as being required for Ebola virus …
maturation that emerged from a haploid genetic screen as being required for Ebola virus …
[HTML][HTML] A review of broadly protective monoclonal antibodies to treat Ebola virus disease
P Rijal, FR Donnellan - Current Opinion in Virology, 2023 - Elsevier
Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …
Recent advances in immunotherapies against infectious diseases
D Ramamurthy, T Nundalall, S Cingo… - Immunotherapy …, 2021 - academic.oup.com
Immunotherapies are disease management strategies that target or manipulate components
of the immune system. Infectious diseases pose a significant threat to human health as …
of the immune system. Infectious diseases pose a significant threat to human health as …